Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
2.740
+0.430 (18.61%)
At close: Jun 22, 2026, 4:00 PM EDT
2.700
-0.040 (-1.46%)
Pre-market: Jun 23, 2026, 7:51 AM EDT
Exicure Employees
Exicure had 2 employees as of March 31, 2026. The number of employees decreased by 6 or -75.00% since the number was last reported on December 31, 2025.
Employees
2
Change
-6
Growth
-75.00%
Revenue / Employee
n/a
Profits / Employee
-$4,892,000
Market Cap
17.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 2 | -6 | -75.00% |
| Dec 31, 2025 | 8 | 1 | 14.29% |
| Dec 31, 2024 | 7 | 1 | 16.67% |
| Dec 31, 2023 | 6 | -7 | -53.85% |
| Dec 31, 2022 | 13 | -34 | -72.34% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Werewolf Therapeutics | 39 |
| Curis | 24 |
| Passage Bio | 24 |
| Moleculin Biotech | 17 |
| NewcelX | 12 |
| AEON Biopharma | 8 |
| Pasithea Therapeutics | 5 |
| Tempest Therapeutics | 5 |
XCUR News
- 12 days ago - Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 21 days ago - Exicure receives noncompliance notification from Nasdaq - TheFly
- 21 days ago - Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - GlobeNewsWire
- 2 months ago - Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - GlobeNewsWire
- 2 months ago - Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - GlobeNewsWire
- 3 months ago - Exicure, Inc. Reports Full Year 2025 Financial Results - GlobeNewsWire
- 4 months ago - Exicure announces publication of results from Phase 2 study of burixafor - TheFly
- 4 months ago - Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - GlobeNewsWire